How Tesofensine works
An oral appetite drug with weight-loss trial results and heart-rate and psychiatric risks.
Also called: NS2330, NS-2330, NS 2330.
Fat-loss drugs · Serotonin, norepinephrine and dopamine reuptake inhibitor.
It blocks the pumps that clear serotonin, norepinephrine and dopamine between nerve cells. This can reduce hunger and change mood, sleep and heart rate. It does not work through the GLP-1 pathway.
- Serotonin transporter (SERT): Blocks serotonin reuptake.
- Norepinephrine transporter (NET): Blocks norepinephrine reuptake; may increase heart rate and blood pressure.
- Dopamine transporter (DAT): Blocks dopamine reuptake; human brain scans show transporter occupancy.
Half-life: About 234 hours in an Alzheimer’s population model; active metabolite M1 about 374 hours.
Related to Tesofensine
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- 5-amino-1MQ: An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
- SLU-PP-332: An exercise-mimicking research chemical with mouse benefits and no human dosing trials.
- AOD-9604: A growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- METOPROLOL SUCCINATE tablet, extended release, DailyMed / National Library of Medicine · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Darmerica, LLC - 716152 - 12/08/2025, FDA · FDA · 2025
- Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial., Lancet (London, England) · 2013
- Under-reporting of adverse effects of tesofensine., Astrup A et al. · Lancet (London, England) · 2013
- About the ARTG Search Visualisation Tool, Therapeutic Goods Administration
- Drug Product Database online query, Health Canada
- Sertraline: an antidepressant medicine, NHS
- Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials., Yu H et al. · Obesity (Silver Spring, Md.) · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.